MetaCap

Aspen Neuroscience (ASPE) vs Opus Genetics (IRD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Opus Genetics is the larger company by market cap ($385.7 million vs $361.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASPE-16.59%IRD+8.72%
+19%-2%-23%
Oct 30, 20261 yearNov 20, 2026
ASPE-16.59%IRD+8.72%
+15%-1%-18%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASPE versus IRD key metrics
MetricASPEIRD
Share price$12.42$3.99
Market cap$361.16M$385.65M
1-day change+0.24%-2.21%
YTD return—+98.51%
1-year return—+108.90%
5-year return—-8.28%
EPS (TTM)$-4.89$-1.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$14.20M
Revenue growth (YoY)—+29.15%
Net income (latest FY)—$-49.59M
Operating margin—-271.90%
Net margin—-349.33%
52-week high$14.90$7.07
52-week low$11.20$1.88
Distance from 52-week high-16.64%-43.56%
Analyst consensus—strong_buy
Avg. price target upside—+249.37%
Average volume352.42K2.56M
Shares outstanding29.08M96.65M
Employees12027
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aspen Neuroscience

ASPE stock →

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Opus Genetics

IRD stock →

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

ASPE vs IRD FAQ

Which is bigger, Aspen Neuroscience or Opus Genetics?

Opus Genetics (IRD) is larger, with a market capitalization of $385.65M compared with $361.16M for Aspen Neuroscience (ASPE).

Are Aspen Neuroscience and Opus Genetics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons